Pharmacology/Pharmaceutical Industry | Page 91 of 172 | Links Medicus Content Curation & Alerts in Medicine

Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma

22 Jan, 2021 | 07:59h | UTC

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

Commentary on Twitter

NEW Research—#Benralizumab significantly reduced exacerbation risk by 49% vs placebo (RR estimate 0·51, 95% CI 0·39–0·65; p≤0·0001) over the 24-week treatment period in patients with severe eosinophilic #asthma

The ANDHI study from Tim Harrison & co https://t.co/bQwikpQZvc pic.twitter.com/sS9ab0Mo1R

— The Lancet Respiratory Medicine (@LancetRespirMed) January 4, 2021

Vaccinology in the post−COVID-19 era

21 Jan, 2021 | 01:24h | UTC

Vaccinology in the post−COVID-19 era – Proceedings of the National Academy of Sciences

Randomized trial: Oral Rimegepant for preventive treatment of migraine

21 Jan, 2021 | 01:04h | UTC

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Rimegepant bests placebo for preventing migraine – MedicalXpress

Against placebo? It would be interesting to know how this new drug works against other established treatments.

Randomized trial: Repeated Ketamine administration for chronic posttraumatic stress disorder

21 Jan, 2021 | 01:03h | UTC

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)

Commentaries: Repeated Ketamine Infusions Reduce Symptom Severity in Individuals With Chronic Post-Traumatic Stress Disorder – Mount Sinai AND Repeated Ketamine Infusions May Rapidly Reduce Chronic PTSD Symptoms – Psychiatry News Alert

Commentary on Twitter

Patients with chronic PTSD given repeated infusions of ketamine over 2 weeks showed significantly greater symptom improvement than those given a psychoactive placebo control infusion, the first evidence of efficacy.
Learn More: https://t.co/qqcIsNfCHC pic.twitter.com/r7Bggz4cIj

— Journals of The American Psychiatric Association (@APAPubJournals) January 5, 2021

Randomized non-inferiority study: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection

21 Jan, 2021 | 01:01h | UTC

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study – The Lancet (link to abstract – $ for full-text)

Commentary (thread – click for more)

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with #HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study: https://t.co/4SdfnRRCje

— The Lancet (@TheLancet) December 21, 2020

Meta-Analysis: Low-intensity warfarin may be an option for patients under 65 years of age with non-valvular atrial fibrillation

21 Jan, 2021 | 00:57h | UTC

Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation – The American Journal of Cardiology (link to abstract – $ for full-text)

[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors

21 Jan, 2021 | 00:37h | UTC

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: PARP Inhibitors Linked With Blood Cancer Risk — Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden – MedPage Today

Commentary on Twitter

NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c

— The Lancet Haematology (@TheLancetHaem) December 21, 2020

Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19

20 Jan, 2021 | 01:55h | UTC

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Discontinuing vs. Continuing ACEIs, ARBs in Patients Admitted With COVID-19 – American College of Cardiology

Randomized trial: Dabigatran non-inferior to standard of care for children with acute venous thromboembolism

21 Jan, 2021 | 00:35h | UTC

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial – The Lancet Haematology (link to abstract – $ for full-text)

SARS-CoV-2 vaccines: Much accomplished, much to learn

20 Jan, 2021 | 01:51h | UTC

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn – Annals of Internal Medicine

Commentary on Twitter

New, from Dr. Fauci & colleagues

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn https://t.co/yguZOquGJF pic.twitter.com/OIBouGS6dr

— Ilan Schwartz is on🦋 (@GermHunterMD) January 18, 2021

Perspective: Covid-19 vaccine guidance for those who are lactating is based on faulty assumptions, experts say

20 Jan, 2021 | 01:40h | UTC

Covid-19 vaccine guidance for those who are lactating is based on faulty assumptions, experts say – STAT

Systematic review on prophylaxis for COVID-19: Hydroxychloroquine does not work, little evidence regarding other drugs

20 Jan, 2021 | 01:38h | UTC

Prophylaxis for COVID-19: a systematic review – Clinical Microbiology and Infection

Guideline synopsis: Initiating Pharmacologic Treatment in Tobacco-Dependent Adults

20 Jan, 2021 | 01:31h | UTC

Initiating Pharmacologic Treatment in Tobacco-Dependent Adults – JAMA (free for a limited period)

Author Interview: Pharmacologic Management of Tobacco Cessation

Original Guideline: Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline – American Journal of Respiratory and Critical Care Medicine

Systematic review: Insufficient evidence of benefit from immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults

20 Jan, 2021 | 01:11h | UTC

IR methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults – Cochrane Library

Original study: Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults – Cochrane Library

Systematic review: Intra-articular ketamine for postoperative analgesia

20 Jan, 2021 | 01:13h | UTC

A Systematic Review of Intra-Articular Ketamine for Postoperative Analgesia – American Journal of Physical Medicine & Rehabilitation

Commentary on Twitter

What is the impact of intra-articular ketamine for postoperative analgesia?https://t.co/61ECP4EOZ2 #physiatry #rehab #painmanagement #ketamine pic.twitter.com/wEQhUvyd8E

— AJPM&R (@AJPMRjournal) November 16, 2020